tiprankstipranks
Trending News
More News >
Tourmaline Bio (TRML)
NASDAQ:TRML
US Market
Advertisement

Tourmaline Bio (TRML) Stock Forecast & Price Target

Compare
587 Followers
See the Price Targets and Ratings of:

TRML Analyst Ratings

Moderate Buy
10Ratings
Moderate Buy
5 Buy
5 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Tourmaline
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

TRML Stock 12 Month Forecast

Average Price Target

$48.79
▲(61.66% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Tourmaline Bio in the last 3 months. The average price target is $48.79 with a high forecast of $65.00 and a low forecast of $35.00. The average price target represents a 61.66% change from the last price of $30.18.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"12":"$12","39":"$39","66":"$66","25.5":"$25.5","52.5":"$52.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$65.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$35.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[12,25.5,39,52.5,66],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,26.756923076923076,29.943846153846152,33.13076923076923,36.31769230769231,39.504615384615384,42.691538461538464,45.878461538461536,49.065384615384616,52.252307692307696,55.43923076923077,58.62615384615385,61.81307692307693,{"y":65,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,25.51,27.45,29.39,31.33,33.269999999999996,35.21,37.15,39.09,41.03,42.97,44.91,46.85,{"y":48.79,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,23.57,24.44923076923077,25.32846153846154,26.20769230769231,27.086923076923078,27.966153846153848,28.845384615384617,29.724615384615383,30.603846153846156,31.483076923076922,32.362307692307695,33.24153846153846,34.12076923076923,{"y":35,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.34,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.85,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.66,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.06,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":13.09,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.83,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$65.00Average Price Target$48.79Lowest Price Target$35.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TRML
LifeSci Capital
LifeSci Capital
$48
Hold
59.05%
Upside
Assigned
09/09/25
Hold Rating Maintained Amidst Novartis's Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
Guggenheim Analyst forecast on TRML
Guggenheim
Guggenheim
Hold
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Buy at GuggenheimTourmaline Bio downgraded to Neutral from Buy at Guggenheim
Wedbush
$48
Hold
59.05%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Outperform at WedbushTourmaline Bio downgraded to Neutral from Outperform at Wedbush
Truist Financial Analyst forecast on TRML
Truist Financial
Truist Financial
Buy
Reiterated
09/09/25
Truist Financial Remains a Buy on Tourmaline Bio (TRML)
Chardan Capital Analyst forecast on TRML
Chardan Capital
Chardan Capital
$48
Hold
59.05%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Buy at ChardanTourmaline Bio downgraded to Neutral from Buy at Chardan
Jefferies Analyst forecast on TRML
Jefferies
Jefferies
$64$47.5
Hold
57.39%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Hold from Buy at JefferiesTourmaline Bio downgraded to Hold from Buy at Jefferies
Leerink Partners Analyst forecast on TRML
Leerink Partners
Leerink Partners
Buy
Reiterated
09/02/25
Tourmaline Bio's Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024
H.C. Wainwright Analyst forecast on TRML
H.C. Wainwright
H.C. Wainwright
$50
Buy
65.67%
Upside
Reiterated
08/15/25
Tourmaline Bio's Strategic Advancements and Promising Clinical Trial Results Reinforce Buy RatingOur 12-month price target is derived from an estimated market value of the firm at $1.30B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.04B for pacibekitug, using a 15% discount rate and 2% terminal growth rate, and $256.3M cash. Assigned probability of approval is 35% for pacibekitug in TED. Assuming 25.7M shares outstanding at the end of 2Q26, this yields a value of approximately $50 per share.
BMO Capital Analyst forecast on TRML
BMO Capital
BMO Capital
$35
Buy
15.97%
Upside
Reiterated
07/28/25
BMO Capital Remains a Buy on Tourmaline Bio (TRML)Investor Meetings Highlight Inflection Point in <12mo; We See Takeout as Very Likely
Piper Sandler Analyst forecast on TRML
Piper Sandler
Piper Sandler
$65
Buy
115.37%
Upside
Reiterated
07/23/25
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN)
Cantor Fitzgerald Analyst forecast on TRML
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
04/23/25
Cantor Fitzgerald reiterates Overweight Rating on Tourmaline Bio (TRML)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and {REMOVEPT} price target on Tourmaline Bio (NASDAQ: TRML).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
LifeSci Capital Analyst forecast on TRML
LifeSci Capital
LifeSci Capital
$48
Hold
59.05%
Upside
Assigned
09/09/25
Hold Rating Maintained Amidst Novartis's Strategic Acquisition of Tourmaline Bio: Balancing Opportunities and Risks
Guggenheim Analyst forecast on TRML
Guggenheim
Guggenheim
Hold
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Buy at GuggenheimTourmaline Bio downgraded to Neutral from Buy at Guggenheim
Wedbush
$48
Hold
59.05%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Outperform at WedbushTourmaline Bio downgraded to Neutral from Outperform at Wedbush
Truist Financial Analyst forecast on TRML
Truist Financial
Truist Financial
Buy
Reiterated
09/09/25
Truist Financial Remains a Buy on Tourmaline Bio (TRML)
Chardan Capital Analyst forecast on TRML
Chardan Capital
Chardan Capital
$48
Hold
59.05%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Neutral from Buy at ChardanTourmaline Bio downgraded to Neutral from Buy at Chardan
Jefferies Analyst forecast on TRML
Jefferies
Jefferies
$64$47.5
Hold
57.39%
Upside
Downgraded
09/09/25
Tourmaline Bio downgraded to Hold from Buy at JefferiesTourmaline Bio downgraded to Hold from Buy at Jefferies
Leerink Partners Analyst forecast on TRML
Leerink Partners
Leerink Partners
Buy
Reiterated
09/02/25
Tourmaline Bio's Promising Drug Developments and Strategic Positioning Make It a Top Pick for 2024
H.C. Wainwright Analyst forecast on TRML
H.C. Wainwright
H.C. Wainwright
$50
Buy
65.67%
Upside
Reiterated
08/15/25
Tourmaline Bio's Strategic Advancements and Promising Clinical Trial Results Reinforce Buy RatingOur 12-month price target is derived from an estimated market value of the firm at $1.30B. This includes a discounted cash flow (DCF) analysis-based asset value of $1.04B for pacibekitug, using a 15% discount rate and 2% terminal growth rate, and $256.3M cash. Assigned probability of approval is 35% for pacibekitug in TED. Assuming 25.7M shares outstanding at the end of 2Q26, this yields a value of approximately $50 per share.
BMO Capital Analyst forecast on TRML
BMO Capital
BMO Capital
$35
Buy
15.97%
Upside
Reiterated
07/28/25
BMO Capital Remains a Buy on Tourmaline Bio (TRML)Investor Meetings Highlight Inflection Point in <12mo; We See Takeout as Very Likely
Piper Sandler Analyst forecast on TRML
Piper Sandler
Piper Sandler
$65
Buy
115.37%
Upside
Reiterated
07/23/25
Analysts Are Bullish on Top Healthcare Stocks: HOYA (HOCPF), Align Tech (ALGN)
Cantor Fitzgerald Analyst forecast on TRML
Cantor Fitzgerald
Cantor Fitzgerald
Buy
Reiterated
04/23/25
Cantor Fitzgerald reiterates Overweight Rating on Tourmaline Bio (TRML)Cantor Fitzgerald analyst Josh Schimmer reiterated an Overweight rating and {REMOVEPT} price target on Tourmaline Bio (NASDAQ: TRML).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Tourmaline Bio

1 Month
xxx
Success Rate
7/11 ratings generated profit
64%
Average Return
+2.74%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +2.74% per trade.
3 Months
xxx
Success Rate
5/8 ratings generated profit
63%
Average Return
+29.45%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +29.45% per trade.
1 Year
Srikripa DevarakondaTruist Financial
Success Rate
11/12 ratings generated profit
92%
Average Return
+41.18%
reiterated a buy rating yesterday
Copying Srikripa Devarakonda's trades and holding each position for 1 Year would result in 91.67% of your transactions generating a profit, with an average return of +41.18% per trade.
2 Years
xxx
Success Rate
11/12 ratings generated profit
92%
Average Return
+55.15%
reiterated a xxx
rating yesterday
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 91.67% of your transactions generating a profit, with an average return of +55.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

TRML Analyst Recommendation Trends

Rating
Apr 25
May 25
Jul 25
Aug 25
Sep 25
Strong Buy
13
21
15
14
6
Buy
3
3
2
1
2
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
25
17
15
8
In the current month, TRML has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. TRML average Analyst price target in the past 3 months is 48.79.
Each month's total comprises the sum of three months' worth of ratings.

TRML Financial Forecast

TRML Earnings Forecast

Next quarter’s earnings estimate for TRML is -$0.94 with a range of -$1.08 to -$0.81. The previous quarter’s EPS was -$0.90. TRML beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.15% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.
Next quarter’s earnings estimate for TRML is -$0.94 with a range of -$1.08 to -$0.81. The previous quarter’s EPS was -$0.90. TRML beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.15% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.
No data currently available

TRML Sales Forecast

Next quarter’s sales forecast for TRML is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRML beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.
Next quarter’s sales forecast for TRML is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. TRML beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.40% of the time in the same period. In the last calendar year TRML has Preformed in-line its overall industry.

TRML Stock Forecast FAQ

What is TRML’s average 12-month price target, according to analysts?
Based on analyst ratings, Tourmaline Bio’s 12-month average price target is 48.79.
    What is TRML’s upside potential, based on the analysts’ average price target?
    Tourmaline Bio has 61.66% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is TRML a Buy, Sell or Hold?
          Tourmaline Bio has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.
            What is Tourmaline Bio’s price target?
            The average price target for Tourmaline Bio is 48.79. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $65.00 ,the lowest forecast is $35.00. The average price target represents 61.66% Increase from the current price of $30.18.
              What do analysts say about Tourmaline Bio?
              Tourmaline Bio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of TRML?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis